| Code | CSB-RA006045MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Gimsilumab, targeting colony-stimulating factor 2 (CSF2), also known as granulocyte-macrophage colony-stimulating factor (GM-CSF). CSF2 is a hematopoietic growth factor that regulates the production, differentiation, and function of granulocytes and macrophages. This cytokine plays critical roles in inflammatory responses and immune cell activation, making it a key mediator in various pathological conditions. Dysregulated CSF2 signaling has been implicated in autoimmune diseases, acute respiratory distress syndrome (ARDS), inflammatory lung conditions, and certain malignancies where it contributes to the tumor microenvironment.
Gimsilumab is a fully humanized IgG1 monoclonal antibody that neutralizes GM-CSF activity and has been investigated in clinical trials for conditions including juvenile idiopathic arthritis and COVID-19-associated lung injury. This biosimilar antibody provides researchers with a valuable tool for investigating CSF2-mediated pathways, studying inflammatory disease mechanisms, and exploring therapeutic interventions targeting GM-CSF signaling in preclinical models.
There are currently no reviews for this product.